Economic Analysis of a Pediatric Ventilator-Associated Pneumonia Prevention Initiative in Nicaragua

Table 2

Noncost inputs for cost effectiveness analysis model.

Inputs	Estimate	Source
Prevalence of VAP among ventilated patients	0.227	Matched cohort study
Case fatality ratio (CFR) for VAP cases	0.5	Matched cohort study
CFR for controls	0.1	Matched cohort study
Average length of stay (LOS): VAP case in days	27.9	Matched cohort study
Average LOS: controls in days	10.9	Matched cohort study
Average number of cultures: VAP cases	5.96	Matched cohort study
Average number of cultures: controls	3.04	Matched cohort study
DALYs severe pneumonia (VAP)	0.056	Hsieh et al. [9]
DALYs severe non-VAP illness	0.037	Hsieh et al. [9]
DALYs death	30.5	Hsieh et al. [9]
Life expectancy Nicaragua in years	73	PAHO [16]